Diatech Diabetes announced today that DEKA Research & Development acquired its core assets and intellectual property (IP). DEKA, the firm behind the Sequel Med Tech twiist automated insulin delivery system, developed the underlying drug delivery technology for the recently launched pump. Dean Kamen, co-founder of Sequel and founder of DEKA, commercialized the first wearable insulin […]
Drug-Device Combinations
Ashley McEvoy explains how Insulet is using AI to advance diabetes care
While Ashley McEvoy has only been at the helm of Insulet (Nasdaq:PODD) for five months, she’s already seeing the increasing role of AI in the company’s technology. Speaking during a “CEOs Unplugged” session covering the emergence of AI in medical technology at AdvaMed’s The MedTech Conference in San Diego alongside Stryker CEO Kevin Lobo and […]
Senseonics posts strong preliminary Q3 sales, reverse stock split
Senseonics (NYSE:SENS) today announced preliminary revenues for the third quarter and plans to conduct a reverse stock split. The Germantown, Maryland-based long-term implantable continuous glucose monitor maker expects approximately $8.1 million in revenue for the third quarter of 2025. That marks a 91% uptick from the third quarter of 2024. The company attributed its growth […]
Modular Medical appoints new head of international operations as insulin patch pump advances
Modular Medical (Nasdaq:MODD) announced today that it appointed David Bosshard as its new head of international operations. Bosshard joins the company as it looks to advance its insulin delivery technology. San Diego-based Modular Medical develops pump technology designed for “almost-pumpers.” It targets adults with a user-friendly, affordable design. Modular Medical’s current pump, the MODD1, won […]
Court sides with Medtronic in insulin pump class action suit
A Minnesota judge has dismissed a class action lawsuit alleging securities fraud related to insulin pumps made by Medtronic (NYSE:MDT). Laura M. Provinzino, U.S. District Judge for the District of Minnesota, granted Medtronic’s motion to dismiss the suit initially brought forward by investors in 2022. Provinzino’s dismissal comes about a year-and-a-half after Katherine M. Menendez, […]
ClearPoint Neuro is developing a robotic neuro-navigation system for drug delivery
ClearPoint Neuro (Nasdaq:CLPT) announced today that it is developing a proprietary robotic neuro-navigation system. The Solana Beach, California-based company says its new product category can enable its navigation software to operate the Kuka LBR robotic arm, supporting all minimally invasive cranial surgical procedures. Those include cell and gene therapy infusions, laser catheter placement, biopsy workflows […]
Convatec to invest $1B in R&D including $600M in U.S.
Convatec announced today that it plans to invest more than $1 billion over the next decade to accelerate its R&D efforts around the world. The global, multi-year planned investment includes $600 million going into the U.S. over the next 10 years. London-based Convatec said its planned investment marks a significant milestone in its mission, underlining […]
Elutia closes $88M bioenvelope sale to Boston Scientific
Elutia (Nasdaq:ELUT) announced today that it closed the $88 million sale of its bioenvolope technologies to Boston Scientific. Last month, the Gaithersburg, Maryland-based company announced an agreement to sell its EluPro and CanGaroo drug-eluting bioenvelopes to Boston Scientific in an all-cash deal. It designed these technologies to protect patients receiving implantable medical devices. With the […]
Tandem t:slim X2 pump cleared for use with Lilly’s Lyumjev ultra-rapid insulin
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received approval to deliver Lyumjev ultra-rapid acting insulin with its t:slim X2 pump. Eli Lilly offers the Lyumjev (insulin lispro-aabc injection) ultra-rapid acting insulin. Tandem can now provide its t:slim X2 pump with Control-IQ+ automated insulin delivery technology with the insulin in the U.S. This latest clearance […]
Sequel Med Tech, Arecor ink co-development agreement for ultra-rapid insulin with twiist
Arecor Therapeutics announced today that it signed a co-development with Sequel Med Tech to pair their diabetes offerings. Cambridge, UK-based Arecor develops AT278 (500U/mL) ultra-rapid-acting insulin. The companies struck a deal to pair the insulin with the Sequel twiist automated insulin delivery system. Additionally, the deal includes a financing agreement with Ligand Pharmaceuticals to bring […]










